Open-label, multicenter phase IV study of ribavirin (Copegus) combined with standard treatment to assess correlation between hemoglobin decrease and rate of sustained virological response in patients with chronic hepatitis C.

Trial Profile

Open-label, multicenter phase IV study of ribavirin (Copegus) combined with standard treatment to assess correlation between hemoglobin decrease and rate of sustained virological response in patients with chronic hepatitis C.

Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Jul 2015

At a glance

  • Drugs Ribavirin (Primary) ; Peginterferon alfa-2a
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms ANECO
  • Sponsors Roche
  • Most Recent Events

    • 26 Apr 2014 New source identified and integrated (EudraCT: 2011-001256-10)
    • 31 Mar 2014 According to the ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
    • 06 Aug 2013 Planned End Date changed from 1 Jul 2014 to 1 Feb 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top